This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator.
The aim of this study is to test the efficacy of omega-3 fatty acids (O-3-FA) for treatment of Tourette's syndrome. The hypothesis is that O-3-FA will reduce tics and obsessive-compulsive disorder (OCD) symptoms through serotonergic and anti-inflammatory effects. This will be a 20-week placebo (olive oil)-controlled study (n=20) with escalating doses (from 1.2 to 6 g/d) if no effects are seen. There will be a preliminary assessment followed by a washout period prior to randomization at week 2. Vital signs, tics and OCD clinical rating scales will be used to monitor safety and efficacy. After the final treatment (visit 11), the 'drug' will be tapered over a 5-day period, discontinued, and the patient will be monitored for an additional 4 weeks. Several subjects have been enrolled on the GCRC under this protocol. The investigators report that no serious safety issues have occurred to date.
Showing the most recent 10 out of 470 publications